Menu Back toSession-0102-Future-Direction-of-Global-Drug-Development-With-ICH-E17-Guideline-Focusing-on-MRCTs

The 7th DIA China Annual Meeting

Session 0102 Future Direction of Global Drug Development With ICH E17 Guideline Focusing on MRCTs

Session Chair(s)

Yoshiaki  Uyama, PhD, RPh

Yoshiaki Uyama, PhD, RPh

  • Director, Office of Medical Informatics and Epidemiology
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

General principles on planningdesigning Multi-Regional Clinical Trials E17


Lih-Jiuan  Hsu

Impacts of E17 Guideline for Drug Review and Approval in Taiwan

Lih-Jiuan Hsu

  • Director, Center of Consultation
  • Center for Drug Evaluation, Taiwan
Patrick  Brady, PharmD

Global Drug Development Impact of ICH E17 Guideline_An Industry Perspective

Patrick Brady, PharmD

  • Vice President, Regulatory Affairs Head, Regulatory Policy and Intelligence
  • Bayer AG Pharmaceuticals, Germany

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU:, or Sofie Peeters:
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
Tel: +86 10 5704 2650